181 related articles for article (PubMed ID: 17408819)
1. Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity.
Carra JH; Wannemacher RW; Tammariello RF; Lindsey CY; Dinterman RE; Schokman RD; Smith LA
Vaccine; 2007 May; 25(21):4149-58. PubMed ID: 17408819
[TBL] [Abstract][Full Text] [Related]
2. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
Berthold I; Pombo ML; Wagner L; Arciniega JL
Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.
Hassett KJ; Cousins MC; Rabia LA; Chadwick CM; O'Hara JM; Nandi P; Brey RN; Mantis NJ; Carpenter JF; Randolph TW
Eur J Pharm Biopharm; 2013 Oct; 85(2):279-86. PubMed ID: 23583494
[TBL] [Abstract][Full Text] [Related]
6. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.
Peek LJ; Brey RN; Middaugh CR
J Pharm Sci; 2007 Jan; 96(1):44-60. PubMed ID: 16998874
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of tetanus toxoid formulation containing aluminium hydroxide adjuvant against agitation.
Solanki VA; Jain NK; Roy I
Int J Pharm; 2012 Feb; 423(2):297-302. PubMed ID: 22155287
[TBL] [Abstract][Full Text] [Related]
8. Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen.
Thomas JC; O'Hara JM; Hu L; Gao FP; Joshi SB; Volkin DB; Brey RN; Fang J; Karanicolas J; Mantis NJ; Middaugh CR
Hum Vaccin Immunother; 2013 Apr; 9(4):744-52. PubMed ID: 23563512
[TBL] [Abstract][Full Text] [Related]
9. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.
Ophorst OJ; Radosević K; Klap JM; Sijtsma J; Gillissen G; Mintardjo R; van Ooij MJ; Holterman L; Companjen A; Goudsmit J; Havenga MJ
Vaccine; 2007 Aug; 25(35):6501-10. PubMed ID: 17646036
[TBL] [Abstract][Full Text] [Related]
10. Preformulation characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae.
Iyer V; Hu L; Liyanage MR; Esfandiary R; Reinisch C; Meinke A; Maisonneuve J; Volkin DB; Joshi SB; Middaugh CR
J Pharm Sci; 2012 Sep; 101(9):3078-90. PubMed ID: 22538529
[TBL] [Abstract][Full Text] [Related]
11. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response.
Hansen B; Sokolovska A; HogenEsch H; Hem SL
Vaccine; 2007 Sep; 25(36):6618-24. PubMed ID: 17681647
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of ricin vaccine, RVEc™, in a Phase 1 clinical trial.
Pittman PR; Reisler RB; Lindsey CY; Güereña F; Rivard R; Clizbe DP; Chambers M; Norris S; Smith LA
Vaccine; 2015 Dec; 33(51):7299-7306. PubMed ID: 26546259
[TBL] [Abstract][Full Text] [Related]
13. Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.
Zhang T; Yang H; Kang L; Gao S; Xin W; Yao W; Zhuang X; Ji B; Wang J
Hum Vaccin Immunother; 2015; 11(7):1779-87. PubMed ID: 26038805
[TBL] [Abstract][Full Text] [Related]
14. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants.
Ljutic B; Ochs M; Messham B; Ming M; Dookie A; Harper K; Ausar SF
Vaccine; 2012 Apr; 30(19):2981-8. PubMed ID: 22381074
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
[TBL] [Abstract][Full Text] [Related]
16. Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
Morefield GL; Hawkins LD; Ishizaka ST; Kissner TL; Ulrich RG
Clin Vaccine Immunol; 2007 Nov; 14(11):1499-504. PubMed ID: 17715328
[TBL] [Abstract][Full Text] [Related]
17. Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant.
Hutcheon CJ; Becker JO; Russell BA; Bariola PA; Peterson GJ; Stroop SD
Vaccine; 2006 Nov; 24(49-50):7214-25. PubMed ID: 16860908
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.
O'Hara JM; Brey RN; Mantis NJ
Clin Vaccine Immunol; 2013 Jun; 20(6):789-94. PubMed ID: 23515013
[TBL] [Abstract][Full Text] [Related]
19. A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity.
Smallshaw JE; Vitetta ES
Vaccine; 2010 Mar; 28(12):2428-35. PubMed ID: 20074685
[TBL] [Abstract][Full Text] [Related]
20. Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant.
DePaz RA; Henderson I; Advant SJ
Vaccine; 2005 Jul; 23(31):4029-35. PubMed ID: 15963360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
